Stay updated with breaking news from Cara therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cara Therapeutics, Inc. (NASDAQ:CARA – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cara Therapeutics in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst O. Livnat now expects that the biopharmaceutical company will post earnings per share of ($0.22) for […] ....
HC Wainwright reaffirmed their buy rating on shares of Cara Therapeutics (NASDAQ:CARA – Free Report) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $3.60 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Cara Therapeutics’ Q2 2024 earnings at ($0.22) EPS, Q3 2024 earnings at ($0.15) […] ....
HC Wainwright reiterated their buy rating on shares of Cara Therapeutics (NASDAQ:CARA – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $3.60 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Cara Therapeutics’ Q2 2024 earnings at ($0.22) EPS, Q3 2024 earnings […] ....
Needham & Company LLC reissued their buy rating on shares of Cara Therapeutics (NASDAQ:CARA – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Needham & Company LLC currently has a $5.00 price objective on the biopharmaceutical company’s stock. Several other brokerages also recently issued reports on CARA. Canaccord Genuity Group […] ....
Cara Therapeutics (NASDAQ:CARA) Given "Buy" Rating at HC Wainwright themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.